AlphaMol Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 8

AlphaMol General Information

Description

Developer of biological computing technologies intended to speed up modern drug discovery. The company's technologies integrated computation biology, artificial intelligence, and other new technologies in experimental drug screening to develop front-end biological computing methods, coupled with originally innovative biotechnologies, enabling customers in the medical industry to expedite the screening and designing of potent drug candidates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 3605, Block A, Zhongguan Plaza
  • Number 4168 Liuxian Boulevard
  • Shenzhen, Guangdong 201210
  • China
+86 150
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 3605, Block A, Zhongguan Plaza
  • Number 4168 Liuxian Boulevard
  • Shenzhen, Guangdong 201210
  • China
+86 150

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlphaMol Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 17-Nov-2025 Completed Generating Revenue
4. Secondary Transaction - Private 08-Sep-2023 Completed Generating Revenue
3. Early Stage VC (Series A) 24-Aug-2023 Completed Generating Revenue
2. Early Stage VC 25-Nov-2022 Completed Generating Revenue
1. Seed Round 07-May-2021 Completed Startup
To view AlphaMol’s complete valuation and funding history, request access »

AlphaMol Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shanghai Healthcare Capital PE/Buyout Minority
Shenzhen Huaqian Equity Investment Fund Management Venture Capital Minority
ApicHope Pharmaceutical Group Corporation Minority
Invengo Information Technology Company Corporation Minority
New Value Capital (China) Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

AlphaMol Investments (1)

AlphaMol’s most recent deal was a Early Stage VC with Essentia BioSciences for . The deal was made on 01-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Essentia BioSciences 01-Jan-2026 Early Stage VC Biotechnology
To view AlphaMol’s complete investments history, request access »

AlphaMol FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process